Cerenion awarded a key patent on its C-Trend® technology in China
The National Intellectual Property Administration of the P.R.C. (CNIPA) has awarded Cerenion its first patent on C-Trend® in China.
Cerenion's patented technology represents the world’s ﬁrst practical method for measuring the brain function of intensive care patients. The Cerenion C-Trend® reveals the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient. The new patent represents a significant expansion of the protection for the technology on a major future market.
"We are thrilled to receive this key patent and look forward to making our technology available in China", remarks Dr. Jukka Kortelainen, CEO at Cerenion.
Cerenion has filed multiple intellectual property applications on its technology worldwide. So far it has been granted patents in, for example, the European Union, the United States, and Japan.
Cerenion Oy has received support from the European Regional Development Fund of the European Union.
Cerenion Oy Elektroniikkatie 3 90590 Oulu FINLAND
Cerenion Oy Firdonkatu 2 T 63 00520 Helsinki FINLAND